DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-market Study of Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Improvement of Opioid-related Side Effects

Information source: MedtronicNeuro
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nonmalignant Pain; Chronic Pain; Chronic Intractable Pain

Intervention: SynchroMed Infusion System and Intrathecal Morphine Sulfate (Device)

Phase: Phase 4

Status: Terminated

Sponsored by: MedtronicNeuro

Summary

This study compares two different ways to treat pain. The two ways are: 1. continuing to take current pain medication(s) or 2. receiving morphine, a pain medication from a drug pump (a system to deliver drug to your body) that is implanted. None of the procedures or products used in this study are experimental. The length the study will be about 25 weeks (between 5½ to 6½ months). The purpose of this study is to compare pain and opioid side effects between people who get a drug pump and people who do not get a drug pump that will stay on their current pain medication treatment.

Clinical Details

Official title: Post-market, Randomized, Controlled, Prospective Study Evaluating a Treatment Conversion to Low Dose Intrathecal Morphine (IT) From Conventional Medical Management (CMM) for Maintenance of Pain Control and Improvement of Opioid-related Side Effects. (CONVERT Targeted Drug Delivery [TDD])

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Clinical Success

Secondary outcome:

Pain Assessment

Opioid-Related Side Effects

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed and dated Medtronic/IRB approved Informed Consent Form and HIPAA Authorization

prior to any study procedures being performed

- Willing and able to attend visits and comply with the study protocol

- Willing and able to abstain from alcohol consumption for the study duration

- At least 18 years of age

- Male or non-pregnant, non-lactating female

- Currently receiving screening

- Used a stable dose of opioids (no change in type or prescribed frequency or dose) for

30 days prior to the Screening as documented in the medical history

- Used chronic systemic opioids for at least 6 months prior to Screening as documented

in medical history Per investigator's medical assessment and the subject's medical history, the subject is/has:

- A new candidate for chronic intrathecal drug therapy (including no prior

intrathecal/epidural trial for pump infusion therapy)

- A diagnosis of nonmalignant, chronic intractable pain as documented in the medical

history

- Medically stable and able to undergo surgery for implantation of the SynchroMed

Infusion System

- Completed a psychological evaluation within 6 months prior to Screening

Exclusion Criteria:

- Psychological or other health conditions, financial, and/or legal concerns (within 3

months prior to Screening) that would interfere with the subject's ability to fulfill the requirements of the protocol as per the investigator's opinion

- A history of alcohol abuse or any illicit drug use within 2 years prior to Screening

- A positive urine test for illicit drugs at Screening (Exception: If subject has a

physician's prescription for an illicit drug; for example, medical marijuana)

- Known diagnosis of moderate to severe sleep apnea.

- Prescribed Continuous Positive Airway Pressure (CPAP), Adaptive Servo-Ventilation

(ASV) therapy or an oral appliance prescribed for the treatment of moderate to severe sleep apnea (current or previous history)

- An active malignancy or has been diagnosed with cancer and has not been in remission

for at least 1 year prior to screening

- An implanted electrical stimulation device(s) or if the subject is expected to

require one of these during the course of the study

- Planned to enroll or is currently enrolled in another investigational drug or

investigational medical device study or has participated in an investigational drug or medical device study within 30 days prior to Screening Prior to Randomization, a subject will be excluded if:

- Diary does not meet compliance

- Mean diary-reported 12-hour NPRS < 6 (on 0 to 10 scale, as reported over 5 days)

- Positive urine test for alcohol at Baseline

- Negative urine test for opioids at Baseline

- Baseline sleep study (PSG) with SaO2 <=80% for >= 5 consecutive minutes, and/or an

Apnea-Hypopnea Index (AHI) >=15.

Locations and Contacts

Pain Management Services PC, Homewood, Alabama 35209, United States

Napa Pain Institute and Neurovations, Napa, California 94558, United States

IPM Medical Group (Interventional Pain Medical Group), Walnut Creek, California 94598, United States

Compass Research, Orlando, Florida 32806, United States

The Center for Clinical Research, Winston-Salem, North Carolina 27103, United States

University of Virginia Pain Management Center, Charlottesville, Virginia 22908-0710, United States

Additional Information

Starting date: October 2013
Last updated: August 3, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017